Identification of gene expression profiles predicting tumor cell response to L-alanosine

Biochemical Pharmacology

Volumn 66, Issue 4, 2003, Pages 613-621

  Efferth, Thomas ^a   Gebhart, Erich ^b   Ross, Douglas D ^c   Sauerbrey, Axel ^d  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^d FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Hierarchical cluster analysis; L Alanosine; mRNA expression profiling; Multidrug resistance; p53 tumor suppressor

Indexed keywords

5' METHYLTHIOADENOSINE PHOSPHORYLASE; ADENOSINE DERIVATIVE; ALANOSINE; BCR ABL PROTEIN; GLYCOPROTEIN P; MESSENGER RNA; UNCLASSIFIED DRUG;

ARTICLE; CALCULATION; CELL ASSAY; CELL GROWTH; CELL LINE; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA BASE; DRUG EFFECT; GENE CLUSTER; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; HUMAN CELL; IC 50; MOLECULAR DYNAMICS; NUCLEOTIDE SEQUENCE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STUDENT T TEST; TUMOR CELL;

EID: 0142102642     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(03)00341-1     Document Type: Article

References (46)

1. Pollock P.M., Pearson J.V., Hayward N.K. Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions. Genes Chromosomes Cancer. 15:1996;77-88.
2. Smith-Sorensen B., Hovig E. CDKN2A (p16INK4A) somatic and germline mutations. Hum. Mutat. 7:1996;294-303.
3. INK4, methylthioadenosine phosphorylase, and the alpha- and beta-interferons in human pancreatic cell carcinoma lines and its implications for chemotherapy. Cancer Res. 56:1996;1083-1090.
4. Zhang H., Chen Z.H., Savarese T.M. Codeletion of the genes for p16INK4, methylthioadenosine phosphorylase, interferon-alpha1, interferon-beta1, and other 9p21 markers in human malignant cell lines. Cancer Genet. Cytogenet. 86:1996;22-28.
5. Dreyling M.H., Roulston D., Bohlander S.K., Vardiman J., Olopade O.I. Codeletion of CDKN2 and MTAP genes in a subset of non-Hodgkin's lymphoma may be associated with histologic transformation from low-grade to diffuse large-cell lymphoma. Genes Chromosomes Cancer. 22:1998;72-78.
6. Hori Y., Hori H., Yamada Y., Carrera C.J., Tomonaga M., Kamihira S., Carson D.A., Nobori T. The methylthioadenosine phosphorylase gene is frequently co-deleted with the p16 INK4a gene in acute type adult T-cell leukemia. Int. J. Cancer. 75:1998;51-56.
7. Schmid M., Malicki D., Nobori T., Rosenbach M.D., Campbell K., Carson D.A., Carrera C.J. Homozygous deletions of methylthioadenosine phosphorylase (MTAP) are more frequent than p16INK4A (CDKN2) homozygous deletions in primary non-small cell lung cancers (NSCLC). Oncogene. 17:1998;2669-2675.
8. M'soka T.J., Nishioka J., Taga A., Kato K., Kawasaki H., Yamada Y., Yu A., Komada Y., Nobori T. Detection of methylthioadenosine phosphorylase (MTAP) and p16 gene deletion in T cell acute lymphoblastic leukemia by real-time quantitative PCR assay. Leukemia. 14:2000;935-940.
9. Batova A., Diccianni M.B., Novori T., Vu T., Yu J., Bridgeman L., Yu A.L. Frequent deletion in the methylthioadenosine phosphorylase gene in T-cell acute lymphoblastic leukemia: strategies for enzyme-targeted therapy. Blood. 88:1996;3083-3090.
10. Wong Y.F., Chung T.K., Cheung T.H., Nobori T., Chang A.M. MTAP gene deletion in endometrial cancer. Gynecol. Obstet. Invest. 45:1998;272-276.
11. Harasawa H., Yamada Y., Kudoh M., Sugahara K., Soda H., Hirakata Y., Sasaki H., Ikeda S., Matsuo T., Tomonaga M., Nobori T., Kamihira S. Chemotherapy targeting methylthioadenosine phosphorylase (MTAP) deficiency in adult T cell leukemia (ATL). Leukemia. 16:2002;1799-1807.
12. Garcia-Castellano J.M., Villanueya A., Healey J.H., Sowers R., Cordon-Cardo C., Huvos A., Bertino J.R., Meyers P., Gorlick R. Methylthioadenosine phosphorylase gene deletions are common in osteosarcoma. Clin. Cancer Res. 8:2002;782-787.
13. Banerjee D., Mayer-Kuckuk P., Capiaux G., Budak-Alpdogan T., Gorlick R., Bertino J.R. Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochim. Biophys. Acta. 1587:2002;164-173.
14. Murthy Y.K., Thiemann J.E., Coronelli C., Sensi P. Alanosine, a new antiviral and antitumour agent isolated from a Streptomyces. Nature. 211:1966;1198-1199.
15. Duan Z., Feller A.J., Penson R.T., Chabner B.A., Seiden M.V. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin. Cancer Res. 5:1999;3445-3453.
16. Luker K.E., Pica C.M., Schreiber R.D., Piwnica-Worms D. Overexpression of IRF9 confers resistance to antimicrotubule agents in breast cancer cells. Cancer Res. 61:2001;6540-6547.
17. Zembutsu H., Ohnishi Y., Tsunoda T., Furukawa Y., Katagiri T., Ueyama Y., Tamaoki N., Nomura T., Kitahara O., Yanagawa R., Hirata K., Nakamura Y. Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res. 62:2002;518-527.
18. Tyagi A.K., Cooney D.A. Identification of the anti-metabolite of L-alanosine, L-alanosyl-5-amino-4-imidazole carboxylic acid ribonucleotide in tumors and assessment of its inhibition of adenylosuccinate synthetase. Cancer Res. 40:1980;4390-4397.
19. Rubinstein L.V., Shoemaker R.H., Paull K.D., Simon R.M., Tosini S., Skehan P., Scudiero D.A., Monks A., Boyd M.R. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay vs. a protein assay against a diverse panel of human tumor cell lines. J. Natl. Cancer Inst. 82:1990;1113-1118.
20. O'Connor P.M., Jackman J., Bae I., Myers T.G., Fan S., Mutoh M., Scudiero D.A., Monks A., Sausville E.A., Weinstein J.N., Friend S., Fornace A.J. Jr., Kohn K.W. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 57:1997;4285-4300.
21. Scherf U., Ross D.T., Waltham M., Smith L.H., Lee J.K., Tanabe L., Kohn K.W., Reinhold W.C., Myers T.G., Andrews D.T., Scudiero D.A., Eisen M.B., Sausville E.A., Pommier Y., Botstein D., Brown P.O., Weinstein J.N. A gene expression database for the molecular pharmacology of cancer. Nat. Genet. 24:2000;236-244.
22. Efferth T. The human ATP-binding cassette transporter genes: from the bench to the bedside. Curr. Mol. Med. 1:2001;45-65.
23. Brügger D., Herbart H., Gekeler V., Seitz G., Liu C., Klingebiel T., Orlikowsky T., Einsele H., Denzlinger C., Bader P., Niethammer D., Beck J.F. Functional analysis of P-glycoprotein and multidrug resistance associated protein related multidrug resistance in AML-blasts. Leuk. Res. 23:1999;467-475.
24. Kimmig A., Gekeler V., Neumann M., Frese G., Handgretinger R., Kardos G., Diddens H., Niethammer D. Susceptibility of multidrug-resistant human leukemia cell lines to human interleukin 2-activated killer cells. Cancer Res. 50:1990;6793-6799.
25. Doyle L.A., Yang W., Abruzzo L.V., Krogmann T., Gao Y., Rishi A.K., Ross D.D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 95:1998;15665-15670.
26. Russell W.C., Newman C., Williamson D.H. A simple cytochemical technique for demonstration of DNA in cells infected with mycoplasmas and viruses. Nature. 253:1975;461-462.
27. Bolton BJ, Packer P, Doyle A. The quality control of cell lines and the prevention, detection and cure of contamination. In: Davis JM, editor. Basic cell culture. A practical approach. Oxford, New York: Oxford University Press; 2002. p. 295-323.
28. Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 48:1988;589-601.
29. Efferth T., Volm M. Reversal of doxorubicin-resistance in sarcoma 180 tumor cells by inhibition of different resistance mechanisms. Cancer Lett. 70:1993;197-202.
30. Efferth T., Fabry U., Osieka R. Anti-Fas/Apo-1 monoclonal antibody CH-11 depletes glutathione and kills multidrug-resistant human leukemic cells. Blood Cells Mol. Dis. 22:1996;2-9.
31. Wosikowski K., Schuurhuis D., Johnson K., Paull K.D., Myers T.G., Weinstein J.N., Bates S.E. Identification of epidermal growth factor receptor and erbB2 pathway inhibitors by correlation with gene expression patterns. J. Natl. Cancer Inst. 89:1997;1505-1515.
32. Hochberg Y., Benjamini Y. More powerful procedures for multiple significance testing. Stat. Med. 9:1990;811-818.
33. Keselman H.J., Cribbie R., Holland B. Controlling the rate of type I error over a large set of statistical tests. Br. J. Math. Stat. Psychol. 55:2002;27-39.
34. Reiner A., Yekutieli D., Benjamini Y. Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics. 19:2003;368-375.
35. Efferth T, Sauerbrey A, Olbrich A, Gebhart E, Rauch P, Weber HO, Hengstler JG, Halatsch ME, Tew KD, Ross DD, Funk JO. Molecular modes of action of artesunate in tumor cell lines. Mol Pharmacol, in press.
36. Efferth T., Miyachi H., Drexler H.G., Gebhart E. Methylthioadenosine phosphorylase as target for chemoselective treatment of T-cell acute lymphoblastic leukemic cells. Blood Cells Mol. Dis. 28:2002;47-56.
37. Volm M., Brüggemann A., Günther M., Kleine W., Pfleiderer A., Vogt-Schaden M. Prognostic relevance of ploidy, proliferation, and resistance-predictive tests in ovarian carcinoma. Cancer Res. 45:1985;5180-5185.
38. Kohn K.W., Jackman J., O'Connor P. Cell cycle control and cancer chemotherapy. Cell Biochem. 54:1994;440-452.
39. Green J.M., MacKenzie R.E., Matthews R.G. Substrate flux through methylenetetrahydrofolate dehydrogenase: predicted effects of the concentration of methylenetetrahydrofolate on its partitioning into pathways leading to nucleotide biosynthesis or methionine regeneration. Biochemistry. 27:1988;8014-8022.
40. Tyagi A.K., Cooney D.A. Identification of the antimetabolite of L-alanosine, L-alanosyl-5-amino-4-imidazolecarboxylic acid ribonucleotide, in tumors and assessment of its inhibition of adenylosuccinate synthetase. Cancer Res. 40:1980;4390-4397.
41. Steegmaier M., Yang B., Yoo J.-S., Huang B., Shen M., Yu S., Luo Y., Scheller R.H. Three novel proteins of the syntaxin/SNAP-25 family. J. Biol. Chem. 273:1998;34171-34179.
42. Roberts T., Chernova O., Cowell J.K. NB4S, a member of the TBC1 domain family of genes, is truncated as a result of a constitutional t(1;10)(p22;q21) chromosome translocation in a patient with stage 4S neuroblastoma. Hum. Mol. Genet. 7:1998;1169-1178.
43. Spies T., Bresnahan M., Strominger J.L. Human major histocompatibility complex contains a minimum of 19 genes between the complement cluster and HLA-B. Proc. Natl. Acad. U.S.A. 86:1989;8955-8958.
44. Handel-Fernandez M.E., Kurimoto I., Streilein J.W., Vincek V. Genetic mapping and physical cloning of UVB susceptibility region in mice. J. Invest. Dermatol. 113:1999;224-229.
45. Serre G., Mils V., Haftek M., Vincent C., Croute F., Reano A., Ouhayoun J.P., Bettinger S., Soleilhavoup J.P. Identification of late differentiation antigens of human cornified epithelia, expressed in re-organized desmosomes and bound to cross-linked envelope. J. Invest. Dermatol. 97:1991;1061-1072.
46. Ahnini R.T., Camp N.J., Cork M.J., Mee J.B., Keohane S.G., Duff G.W., di Giovine F.S. Novel genetic association between the corneodesmosin (MHC S) gene and susceptibility to psoriasis. Hum. Mol. Genet. 8:1999;1135-1140.